Neoadjuvant dose-modified docetaxel in squamous cell carcinoma of the head and neck: A phase 3 study
- 1 March 2020
- journal article
- research article
- Published by Wiley in Oral Diseases
- Vol. 26 (2), 285-294
- https://doi.org/10.1111/odi.13252
Abstract
Objective To evaluate the efficacy and safety of dose-modified docetaxel plus cisplatin and 5-fluorouracil (TPF) in Chinese patients with squamous cell carcinoma of the head and neck (SCCHN). Materials and methods This Phase III, open-label, multi-center study included Chinese adults with previously untreated TNM Stage III or IV SCCHN (NCT00995293). Patients were randomized (1:1) to induction chemotherapy with TPF (docetaxel 60 mg/m(2) and cisplatin 60 mg/m(2) on day 1 and 5-FU 750 mg/m(2) per day continuous IV infusion on days 1-5) or PF (cisplatin 75 mg/m(2) on day 1 and 5-FU 750 mg/m(2) per day on days 1-5) every 3 weeks for 3-4 cycles. The primary endpoint was progression-free survival (PFS). Results Median PFS in the TPF (n = 108) and PF (n = 111) groups was 400 days and 342 days (HR = 0.75; 95% CI, 0.531.06; p = .227), respectively. Overall response rate was higher for TPF versus PF (76.3% vs. 52.9%; p = .001), although this equalized following radiotherapy (75.0% vs. 73.9%). In the TPF and PF groups, >= 1 treatment-emergent adverse event was experienced by 104 (94.5%) and 110 (93.2%) patients, respectively. Conclusion Adding dose-modified docetaxel to PF did not significantly improve PFS but may increase anti-tumor activity in Chinese patients with locally advanced SCCHN.Funding Information
- Sanofi China Investment Company
This publication has 28 references indexed in Scilit:
- Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trialsInternational Journal of Clinical Oncology, 2011
- Head and neck cancer--Part 1: Epidemiology, presentation, and preventionBMJ, 2010
- Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized studyAnnals of Oncology, 2009
- Oral cavity cancers at a young age: Analysis of patient, tumor and treatment characteristics in Chiang Mai University HospitalOral Oncology, 2006
- A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinomaOral Oncology, 2005
- Tongue and tonsil carcinomaCancer, 2005
- Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and NeckThe New England Journal of Medicine, 2004
- Incidence and survival of squamous cell carcinoma of the tongue in Scandinavia, with special reference to young adultsInternational Journal of Cancer, 2002
- Larynx Preservation in Pyriform Sinus Cancer: Preliminary Results of a European Organization for Research and Treatment of Cancer Phase III TrialJNCI Journal of the National Cancer Institute, 1996
- Induction Chemotherapy plus Radiation Compared with Surgery plus Radiation in Patients with Advanced Laryngeal CancerThe New England Journal of Medicine, 1991